quinine dihydrochloride inj, 600 mg/2ml, solution injectable, b/100
pharm-inter sprl - la quinine - solution injectable - 600 mg/2ml
dakasvir, 60 mg, comprimé pelliculé/ film coated tablet, boite de 28
laboratoires pharma 5 - daclatasvir dihydrochloride - comprimé pelliculé/ film coated tablet - 60 mg
montezal, 10 mg/5 mg, comprimé, b/10
oxford laboratories pvt.ltd - montélukast + lévocétirizine dihydrochloride - comprimé - 10 mg/5 mg
remiflu, 2.5 mg /10 mg /500 mg, comprimé pelliculé/ film coated tablet, boite de 10
ipca laboratories ltd. - levocetirizine dihydrochloride + phenylephrine hydrochloride - comprimé pelliculé/ film coated tablet - 2.5 mg /10 mg /500 mg
betahistine viatris 8 mg comp.
viatris gx bv-srl - dichlorhydrate de bétahistine 8 mg - comprimé - 8 mg - dichlorhydrate de bétahistine 8 mg - betahistine
betahistine viatris 16 mg comp.
viatris gx bv-srl - dichlorhydrate de bétahistine 16 mg - comprimé - 16 mg - dichlorhydrate de bétahistine 16 mg - betahistine
fluanxol 1 mg compr. pellic.
lundbeck sa-nv - chlorhydrate de flupentixol 1,168 mg - eq. flupentixol 1 mg - comprimé pelliculé - 1 mg - chlorhydrate de flupentixol 1.168 mg - flupentixol
golaseptine 5 mg compr. à sucer
laboratoires s.m.b. sa-nv - dichlorhydrate de chlorhexidine 5 mg - comprimé à sucer - 5 mg - dichlorhydrate de chlorhexidine 5 mg - chlorhexidine
longifene 25 mg comp.
pierre fabre médicament - chlorhydrate de bulclizine 25 mg - comprimé - 25 mg - chlorhydrate de bulclizine 25 mg - buclizine
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agents antinéoplasiques - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.